OncoMatch/Clinical Trials/NCT05914389

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

Is NCT05914389 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Oxaliplatin and Capecitabine for colon neoplasm.

Phase 2RecruitingSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05914389Data as of Jun 2026Location: China

Treatment: Oxaliplatin · Capecitabine · Anti-PD-L1 Monoclonal Antibody · Clostridium butyricum — This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

OxaliplatinCapecitabine

Other

Anti-PD-L1 Monoclonal AntibodyClostridium butyricum

Disease stage

Required: Stage T1-4N+

Performance status

ASA 0–3

Demographics

Ages ≤ 75

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05914389 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage T1-4N+ is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify